BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

Despite negative results of clinical trials conducted on the overall population of patients with gastric cancer, PARP inhibitor (PARPi) therapeutic strategy still might represent a window of opportunity for a subpopulation of patients with gastric cancer. An estimated 7% to 12% of gastric cancers ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Annalisa, Rizzolio, Sabrina, Pietrantonio, Filippo, Bellomo, Sara E., Benelli, Matteo, De Cecco, Loris, Romagnoli, Dario, Berrino, Enrico, Orrù, Claudia, Ribisi, Salvatore, Moya-Rull, Daniel, Migliore, Cristina, Conticelli, Daniela, Maina, Irene M., Puliga, Elisabetta, Serra, Violeta, Pellegrino, Benedetta, Llop-Guevara, Alba, Musolino, Antonino, Siena, Salvatore, Sartore-Bianchi, Andrea, Prisciandaro, Michele, Morano, Federica, Antista, Maria, Fumagalli, Uberto, De Manzoni, Giovanni, Degiuli, Maurizio, Baiocchi, Gian Luca, Amisano, Marco F., Ferrero, Alessandro, Marchiò, Caterina, Corso, Simona, Giordano, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183806/
https://www.ncbi.nlm.nih.gov/pubmed/37129948
http://dx.doi.org/10.1158/0008-5472.CAN-22-2620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183806/
https://www.ncbi.nlm.nih.gov/pubmed/37129948
http://dx.doi.org/10.1158/0008-5472.CAN-22-2620

Ejemplares similares